文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

单侧晚期视网膜母细胞瘤诊断时低风险组织病理学特征的临床预测因素

Clinical Predictors at Diagnosis of Low-Risk Histopathology in Unilateral Advanced Retinoblastoma.
PubMed 文献 · Ophthalmology · 2019-04-12

该回顾性单中心观察性病例系列纳入2008年1月至2018年2月在多伦多儿童医院因单侧cT2b/D组视网膜母细胞瘤行初次眼球摘除的38只眼,分析诊断时临床特征与低风险(pT1/pT2)或高风险(pT3/pT4)组织病理学的相关性。黄斑未受累、视神经可见及视网膜脱离小于1个象限的预测低风险组织病理学概率均为100%,而临床体征均不能预测高风险组织病理学特征。

要点

  • 黄斑未受累(7/7)、视神经可见(10/10)、视网膜脱离小于1个象限(10/10)预测低风险组织病理学特征的概率均为100%。
  • 存在黄斑受累、视神经完全遮蔽或视网膜脱离时,高风险组织病理学特征比例分别为13%(4/31)、15%(4/27)和14%(4/28)。
  • 无临床体征可预测高风险组织病理学特征。

核心结论

  • 黄斑未受累、视神经可见、视网膜脱离小于1个象限或三者组合可预测初次眼球摘除时的低风险组织病理学特征,提示可安全尝试保眼治疗。
  • 无临床体征可预测高风险组织病理学特征。
  • 1例缺乏全部3项低风险临床预测特征且组织病理学为高风险(pT3a)的患儿发生转移并死亡,其余患儿存活且健康状况良好(平均随访65个月)。

研究设计与样本

  • 回顾性、非比较性、单机构观察性病例系列。
  • 纳入2008年1月至2018年2月在加拿大多伦多儿童医院因单侧cT2b/D组视网膜母细胞瘤行初次眼球摘除的儿童。
  • 共38只眼符合条件;从诊断到眼球摘除的中位间隔为4天(范围0-14天)。

主要发现

  • 组织病理学诊断高风险4只眼(10.5%),低风险34只眼(89.5%)。
  • 高风险眼表现为大量脉络膜侵犯(4/38)或经巩膜、眼外及筛板后视神经侵犯(1/38)。
  • 临床发现包括黄斑受累(31/38)、视神经完全遮蔽(27/38)和视网膜脱离(28/38)。
  • 黄斑受累眼的高风险组织病理学特征比例为13%(4/31;95%CI 1%-25%),视神经完全遮蔽眼为15%(4/27;95%CI 1%-28%),视网膜脱离眼为14%(4/28;95%CI 1%-27%)。

关键数值与推荐

  • 黄斑未受累预测低风险组织病理学特征的概率为100%(7/7;95%CI 47%-100%)。
  • 视神经可见预测低风险组织病理学特征的概率为100%(10/10;95%CI 63%-100%)。
  • 视网膜脱离小于1个象限预测低风险组织病理学特征的概率为100%(10/10;95%CI 63%-100%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Attempted eye salvage for unilateral (cT2b/group D) retinoblastoma may risk tumor spread compared with primary enucleation. Identification of clinical features predictive of low histopathologic risk support safe trial salvage. DESIGN: Retrospective, noncomparative single-institutional observational case series. PARTICIPANTS: Children with unilateral cT2b/group D retinoblastoma managed with primary enucleation at the Hospital for Sick Children, Toronto, Canada, January 2008 through February 2018. METHODS: Data included clinical features (intraocular pressure, optic nerve obscuration, macular involvement, tumor seeding, and serous retinal detachment [RD] >1 quadrant), timing to enucleation, histopathologic features, and follow-up. MAIN OUTCOME MEASURES: Primary outcome was low-risk (LR; pT1/pT2) versus high-risk (HR; pT3/pT4) histopathologic features with clinicopathologic correlations. Secondary outcomes were positive predictive (probability that certain clinical features would predict LR histopathologic features) and negative predictive values (probability that absence of these clinical features would predict HR histopathologic features). RESULTS: Thirty-eight eyes were eligible and showed vitreous seeding and normal intraocular pressure. The median diagnosis to enucleation interval was 4 days (range, 0-14 days). Histopathologic analysis diagnosed 4 (10.5%) HR and 34 (89.5%) LR eyes. High-risk eyes demonstrated massive choroidal invasion (4/38) or trans-scleral, extraocular, and postlaminar optic nerve invasion (1/38). Clinical findings included macular involvement (31/38), complete optic nerve obscuration (27/38), and RD (28/38). The proportion of eyes with HR histopathologic features was 13% (4/31; 95% confidence interval [CI], 1%-25%) with macular involvement, 15% (4/27; 95% CI, 1%-28%) with complete optic nerve obscuration, and 14% (4/28; 95% CI, 1%-27%) with RD. The predictability of LR histopathologic features was 100% with macular sparing (7/7; 95% CI, 47%-100%), optic nerve visibility (10/10; 95% CI, 63%-100%), and less than 1 quadrant of RD (10/10; 95% CI, 63%-100%). In 1 child lacking all 3 clinical LR predictive features with HR histopathologic features (pT3a), metastases developed and the patient died; other children are alive and well (mean follow-up, 65 months). CONCLUSIONS: Presence of macular sparing, optic nerve visibility, less than 1 quadrant of RD, or a combination thereof predicted LR histopathologic features at primary enucleation, suggesting safe trial eye salvage. No clinical sign predicted HR histopathologic features.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Kletke SN, Feng ZX, Hazrati LN, et al. Clinical Predictors at Diagnosis of Low-Risk Histopathology in Unilateral Advanced Retinoblastoma. Ophthalmology. 2019. PMID: 30986443. doi:10.1016/j.ophtha.2019.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。